首页|期刊导航|中华医学杂志（英文版）|Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer:a prospective observational study

Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer:a prospective observational study

王莉廖美琳李龙芸万欢英徐农刘基巍梁厚杰

中华医学杂志（英文版）Issue(11)：1607-1610,4.

Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer:a prospective observational study

王莉 ¹廖美琳 ²李龙芸 ³万欢英 ⁴徐农 ⁵刘基巍 ⁶梁厚杰⁷

作者信息

1. Department of Medicine, Eli Lilly Asia Inc., Shanghai 200021, China
2. Clinical Medical Centre of Lung Tumour, Shanghai Chest Hospital, Shanghai 200030, China
3. Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100730, China
4. Department of Respiratory Medicine, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
5. Department of Respiratory Medicine, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
6. Department of Respiratory Medicine, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China
7. Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400030, China
折叠

摘要

Abstract

Background　Platinum-based chemotherapy has been proved effective in patients with advanced non-small cell lung cancer (NSCLC). This study evaluated the effectiveness and safety of first-line chemotherapy with gemcitabine plus cisplatin (GEM-Cis) 3-week regimen in routine care of Chinese patients with advanced NSCLC.Methods　Two hundred and twenty-one patients with NSCLC stage IIIb or IV were enrolled and 209 were eligible foreffectiveness and safety analysis. The median age was 58 (range 29 to 79) years. The percents of cases in stage Ⅳ and stage Ⅲb were 52.2% and 47.8%; of Karnofsky performance score (KPS) less than 80 and 80-100 were 37.3% and 62.7% and of adeno-cancer and non-adeno-cancer were 59.8% and 40.2%. The average number of completed chemotherapy cycles was three. Measures of effectiveness included clinical benefit, significant clinical response (SCR) and adverse effects of GEM-Cis in the treatment of NSCLC at stages Ⅲb/Ⅳ.Results　KPS increased from 79±9 at baseline to 86±10 after chemotherapy (P<0.01). Lung cancer symptom scale (LCSS) score of pain, dyspnea and cough increased from 77±24, 74±22 and 63±19 to 92±15, 90±14 and 86±15, respectively (P<0.01). The clinical benefit rate was 85.2% ［95% confidence interval (CI) 80.3%-90.0%］. The SCR was 89.5% (95% CI 85.3%-93.7%). Median survival time was 7.8 months (95% CI 7.1 months-9.1 months). Sixty-four patients (30.6%) experienced an adverse effect that was deemed clinically significant. Only one patient (0.5%) was hospitalized due to chemotherapy related adverse effects. Life-threatening toxicity was observed in two patients (1.0%).Conclusion　First-line chemotherapy with GEM-Cis in the routine care of Chinese patients with advanced NSCLC is effective and safe.

关键词

non-small cell lung cancer/drug therapy/gemcitabine/cisplatin

Key words

non-small cell lung cancer/drug therapy/gemcitabine/cisplatin

分类

医药卫生

引用本文复制引用

王莉,廖美琳,李龙芸,万欢英,徐农,刘基巍,梁厚杰..Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer:a prospective observational study[J].中华医学杂志（英文版）,2004,(11):1607-1610,4.

基金项目

This study is funded by Eli Lilly Asia Inc.and accomplished with support from investigators of 39 major hospitals in China. （）

中华医学杂志（英文版）

OACSTPCDMEDLINESCI

ISSN：0366-6999

访问量2

下载量0

段落导航